Slow Subcutaneous Release of Glatiramer Acetate or CD40-Targeting Peptide KGYY6 Is More Advantageous in Treating Ongoing Experimental Autoimmune Encephalomyelitis
Slow-release formulations of both GA and KGYY<sub>6</sub> vastly improve the efficacy of both, and KGYY<sub>6</sub> is more consistent in efficacy across different lots.
Authors
- David H. Wagner (ORCID: https://orcid.org/0000-0002-3853-8039)
- Gisela M. Vaitaitis
Institutions
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Neurology International
- Published
- 2024-11-20
- DOI
- https://doi.org/10.3390/neurolint16060114
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Diabetes and Digestive and Kidney Diseases